Cell Therapy Company Achieves Commercial Manufacturing
Journey from clinical to commercial cell therapy manufacturing through CDMO collaboration.
1 min read1576 viewsPublished June 10, 2025
Cell Therapy Company Achieves Commercial Manufacturing
Overview
An innovative cell therapy company transitioned from Phase 3 clinical supply to commercial manufacturing for an autologous CAR-T therapy.
Challenges Faced
- Complex, patient-specific manufacturing
- Strict chain of custody requirements
- Vein-to-vein timing constraints
Solution Architecture
Manufacturing Network Design
- Hub-and-spoke model with regional facilities
- Centralized quality oversight
- Distributed manufacturing for patient access
Technology Implementation
- Closed, automated manufacturing system
- Real-time batch tracking
- Electronic batch records
Outcomes
- 98% manufacturing success rate
- 14-day average vein-to-vein time
- Successful regulatory approvals in US, EU, Japan
Lessons Learned
- Early investment in automation pays dividends
- Regional manufacturing improves patient access
- Integrated IT systems enable tracking
Was this article helpful?
Sign in to provide feedback